Valerio Therapeutics Finalizes Acquisition of Etherna Immunotherapies to Build RNA Platform

Key Facts

1Valerio Therapeutics announced the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies.

2The closing follows the payment of the cash consideration for the acquisition which occurred in August.

Valerio Therapeutics announced the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies. BusinessWire reported that the closing follows the payment of the cash consideration for the transaction, which occurred in August.

The acquisition aims to create an integrated targeted RNA platform by combining precision-guided RNA technologies with Etherna's immunotherapies. This strategic move is intended to accelerate progress toward clinical trials, leveraging the combined capabilities of both entities in the biotechnology sector.